The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: Studies in vitro

Physiological Research

Volumn 53, Issue 6, 2004, Pages 683-691

  Schroterova L ^a   Kaiserova H ^a   Baliharova V ^a   Velik J ^a   Gersl V ^b   Kvasnickova E ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cytosolic reductases; Iron chelators; Oxidative stress; P450; Pyridoxal isonicotinoyl hydrazone

Indexed keywords

ALDEHYDE REDUCTASE; ANTHRACYCLINE ANTIBIOTIC AGENT; CARBONYL REDUCTASE; CHELATING AGENT; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B; CYTOCHROME P450 3A; DAUNORUBICIN; DIHYDRODIOL DEHYDROGENASE; DOXORUBICIN; LACTATE DEHYDROGENASE; OXIDOREDUCTASE; OXYGEN RADICAL; PYRIDOXAL ISONICOTINOYLHYDRAZONE; SALICYLALDEHYDE ISONICOTINOYLHYDRAZONE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG METABOLISM; DRUG STRUCTURE; IN VITRO STUDY; LIVER CELL; NONHUMAN; OXIDATIVE STRESS; RABBIT; SPECTROPHOTOMETRY;

ALDEHYDES; ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CHELATING AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HEPATOCYTES; HYDRAZONES; ISONIAZID; MALE; OXIDOREDUCTASES; PYRIDOXAL; RABBITS;

EID: 11244327041     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. ADAMCOVÁ M, MACHÁČKOVÁ J, GERŠL V, PELOUCH V, ŠIMŮNEK T, KLIMTOVÁ I, HRDINA R, POŇKA P: Cardiac troponin T following repeated administration of pyridoxal isonicotinoyl hydrazone in rabbits. Physiol Res 51. 443-448, 2002.
2. AX W, SOLDAN M, KOCH L, MASER E: Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 59: 293-300, 2000.
3. BLÁHA K, CIKRT M, NERUDOVÁ J, POŇKA HF: Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone. Blood 91: 4368-4372, 1998.
4. BRITTENHAM GM: Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration. Semin Hematol 27: 112-116, 1990.
5. BUZDAR AU, MARCUS C, SMITH TL, BLUMENSCHEIN GR: Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55: 2761-2775, 1985.
6. CHABEREK S, MARTELL AE: Organic Sequestering Agents. John Wiley, New York, 1969.
7. CLYNES M: Animal Cell Culture Techniques, Springer, New York, 1998.
8. CUSACK BJ, MUSHLIN PS, VOULELIS LD, LI X, BOUCEK RJ, OLSON RD: Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol? Toxicol Appl Pharmacol 118: 177-185, 1993.
9. DAVISON AN: The mechanism of inhibition of decarboxylases by isonicotinoyl hydrazide. Biochemica Biophysica Acta 19: 131-140, 1956.
10. DUHAULT J, GONNARD P, FENARD S: Study of heterocyclic hydrazones of pyridoxal phosphate. Coenzymic action (in French). Bull Soc Chim Biol (Paris) 49: 177-190, 1967.
11. FORREST GL, GONZALEZ B, TSENG W, LI X, MANN J: Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 60: 5158-5164, 2000.
12. GERŠL V, BAJGAR J, HRDINA R, MAZUROVÁ Y, MACHÁČKOVÁ J, CERMAN J, ŠUBA P: Cholinesterases in dexrazoxane-treated daunorubicin cardiomyopathy in rabbits. Gen Physiol Biophys 18: 335-346, 1999.
13. GILLETTE JR: Techniques for Studying Drug Metabolism In Vitro. In: Fundamentals of Drug Metabolism and Disposition. LADU BN, MANDEL HG, WAY EL (eds), Williams & Wilkins, Baltimore, 1972, pp 400-418.
14. GOEPTAR AR, GROOT EJ, SCHEERENS H, COMMANDEUR JN, VERMEULEN NP: Cytotoxicity of mitomycin C and adriamycin in freshly isolated rat hepatocytes: the role of cytochrome P450. Cancer Res 54: 2411-2418, 1994.
15. HOY T, HUMPHRYS J, JACOBS A, WILLIAMS A, PONKA P: Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. Br J Haematol 43: 443-449, 1979.
16. LEE KW, KO BC, JIANG Z, CAO D, CHUNG SS: Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anticancer Drugs 12: 129-132, 2001.
17. LOMBARDO T, FERRO G, FRONTINI V, PERCOLLA S: High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration. Am J Hematol 51: 90-92, 1996.
18. MAGRO AM, BRAI M: Evidence for lipoxygenase activity in induction of histamine release from rat peritoneal mast cells by chelated iron. Immunology 49: 1-8, 1983.
19. MARTIN A, CLYNES M: Comparison of 5 microplate colorimetric assays for in vitro cytotoxicity testing and cell proliferation assays. Cytotechnology 11: 49-58, 1993.
20. MASER E, BANNENBERG G: 11 beta-hydroxysteroid dehydrogenase mediates reductive metabolism of xenobiotic carbonyl compounds. Biochem Pharmacol 47: 1805-1812, 1994.
21. MINOTTI G, CAIRO G, MONTI E: Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J 13: 199-212, 1999.
22. MORDENTE A, MEUCCI E, MARTORANA GE, GIARDINA B, MINOTTI G: Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 52: 83-88, 2001.
23. OHARA H, MIYABE Y, DEYASHIKI Y, MATSUURA K, HARA A: Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem Pharmacol 50: 221-227, 1995.
24. OLSON RD, MUSHLIN PS: Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4: 3076-3086, 1990.
25. PETERSON GL: Review of the Folin phenol protein quantitation method of Lowry, Rosebrough, Farr and Randall. Anal Biochem 100: 201-220, 1979.
26. PIPPARD MJ: Megaloblastic anaemia: geography and diagnosis. Lancet 344: 6-7, 1994.
27. POŇKA P, BOROVÁ J, NEUWIRT J, FUCHS O: Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 97: 317-321, 1979a.
28. POŇKA P, BOROVÁ J, NEUWIRT J, FUCHS O, NEČAS E: A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta 586: 278-297, 1979b.
29. POŇKA P, RICHARDSON DR, EDWARD JT, CHUBB FL: Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilise iron from reticulocytes in vitro. Can J Physiol Pharmacol 72: 659-666, 1994.
30. POUNA P, BONORON-ADELE S, GOUVERNEUR G, TARIOSSE L, BESSE P, ROBERT J: Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol 117: 1593-1599, 1996.
31. PROPPER D, MASER E: Carbonyl reduction of daunorubicin in rabbit liver and heart. Pharmacol Toxicol 80: 240-245, 1997.
32. PROUGH RA, BURKE MD, MAYER RT: Direct fluorometric methods for measuring mixed function oxidase activity. Methods Enzymol 52: 372-377, 1978.
33. RHODEN W, HASLETON P, BROOKS N: Anthracyclines and the heart. Br Heart J 70: 499-502, 1993.
34. RICHARDSON DR, POŇKA P: Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med 131: 306-315, 1998.
35. SEGLEN PO: Preparation of isolated rat liver cells. Methods Cell Biol 13: 29-83, 1976.
36. SCHULMAN HM, HERMES-LIMA M, WANG EM, PONKA P: In vitro antioxidant properties of the chelators pyridoxal isonicotinoyl hydrazone and some of its analogs. Redox Report 1: 373-378, 1995.
37. TESTA B: The Metabolism of Drugs and Other Xenobiotic. Biochemistry of Redox Reactions. Academic Press, London, 1995.
38. WEXLER LH: Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane. Semin Oncol 25: 86-92, 1998.